Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for BIIB/Eisais Leqembi, stating that the slowing of cognitive decline in treated patients does not outweigh the safety risks... More
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM EDTPiper Sandler analyst Christopher Raymond lowered the price target on Biogen (NASDAQ: BIIB) to $307.00 (from $313.00) while maintaining a Overweight rating.
The analyst comments "Conclusion: Remain OW on BIIB shares despite news this morning that the EMAs Committee for Medicinal Products for Human... More
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $282.00 (from $303.00) while maintaining a Outperform rating.
The analyst comments "Our analysis suggests a 20% historical success rate for drugs CHMP re-examines; looking at prior examples over the past 10 years, we... More
Sage Therapeutics stock sinks after drug study failed
July 24, 2024 8:15 AM EDTSAGE Therapeutics (NASDAQ: SAGE) stock price dropped significantly pre-market Wednesday after the company, alongside partner Biogen, announced disappointing results from a late-stage clinical trial for its drug SAGE-324 (BIIB124) for essential tremor (ET).
The Phase 2 KINETIC 2 study failed to meet its primary endpoint, which measured improvement in upper limb tremors. Additionally, no... More
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
July 24, 2024 7:43 AM EDTSAGE Therapeutics (NASDAQ: SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor- No statistically significant differences were demonstrated between any dose of SAGE-324 and... More